References
- Cash BD, Chey WD. Irritable bowel syndrome - an evidence-based approach to diagnosis. Aliment Pharmacol Ther 2004;19:1235-45
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21
- Saito YA, Schoenfeld P, Locke GRI. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-15
- Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
- Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004;10:299-309
- Buono JL, Mathur K, Averitt A, et al. Economic burden of irritable bowel syndrome with diarrhea: retrospective analyses of a US commercially insured population. Poster P1964 presented at the American College of Gastroenterology Annual Scientific Meeting, Honolulu, HI, October 16–21, 2015
- Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Poster K03 presented at the Academy of Managed Care Pharmacy Nexus Meeting, Orlando, FL, October 26–29, 2015
- Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1149-72
- Sayuk GS, Gyawali CP. Irritable bowel syndrome: modern concepts and management options. Am J Med 2015;128:817-27
- Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109(Suppl1):S2-S26
- Guerin A, Carson RT, Lewis B, et al. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population. J Med Econ 2014;17:577-86
- Frank A. IBS in America: Survey Highlights Physical, Social and Emotional Impact. Bethesda, MD, USA: American Gastroenterological Association; 2015
- Hughes PA, Harrington AM, Castro J, et al. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut 2013;62:1456-65
- Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27
- Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003;163:929-35
- Mitra D, Davis KL, Baran RW. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome. Postgrad Med 2011;123:122-32
- Patel RP, Petitta A, Fogel R, et al. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol 2002;35:14-20
- Doshi JA, Cai Q, Buono JL, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm 2014;20:382-90